Compare Li Auto Inc (LI) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Li Auto Inc vs TransMedics Group Inc — how do they compare? Li Auto Inc trades at $11.53 (market cap $10.71B), while TransMedics Group Inc trades at $78.56 (market cap $2.74B). The key difference: Li Auto Inc is far larger — about 3.9× TransMedics Group Inc's market cap, and TransMedics Group Inc is trading nearer its 52-week high, Li Auto Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Li Auto Inc for 101 Days and TransMedics Group Inc for 24 Days on average.
| LI | TMDX | |
|---|---|---|
Market Cap | $10.71B | $2.74B |
Volume | 1,781,143 | 949,331 |
Sector | Consumer Cyclical | Health |
52-Week High | $23.61 | $150.42 |
52-Week Low | $10.69 | $61.99 |
Typical Hold Time | 101 Days | 24 Days |
Enterprise Value | $139.58M | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Li Auto (LI) trades at $11.61, down 5.64% on the day and near 52-week lows amid delivery concerns. The technical picture is bearish with negative moving averages, while fundamentals show revenue declining from $144.5B in 2024 to $112.3B in 2025, though the company maintains a strong balance sheet with $112.8B cash. Recent Q2 2026 earnings missed expectations with a net loss of $0.25 per share, and September deliveries of 31,817 vehicles indicate volume moderation.
The outlook remains challenging with intense EV competition and margin pressure, but analyst consensus suggests 31% upside to the $15.18 price target. Key risks include execution on new model launches (Li i9, MEGA) and China's auto market slowdown, while the company's cash position provides buffer against near-term headwinds.
TransMedics Group (TMDX) trades at $78.17, down 3.58% on the day, with a bearish technical signal and mixed earnings history. The company reported strong 2025 results with $605.49M revenue and $190.29M net income, but 2026 projections show margin compression. Recent news highlights insider buying and leadership changes alongside legal investigations into fiduciary duties, creating a complex sentiment backdrop.
The stock offers growth potential with a consensus price target of $99.75, but faces risks from earnings misses, margin pressure, and ongoing legal scrutiny. Analyst consensus remains bullish with 69% buy ratings, yet investors must weigh robust profitability metrics against execution and regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Li Auto Inc
Li Auto is a leading Chinese NEV manufacturer that designs, develops, manufactures, and sells premium smart NEVs. The company started volume production of its first model Li One in November 2019. The model is a six-seater, large, premium plug-in electric SUV equipped with a range extension system and advanced smart vehicle solutions. It sold over 90,000 EVs in 2021, accounting for about 2.7% of China's passenger new energy vehicle market. Beyond Li One, the company will expand its product line, including both BEVs and PHEVs, to target a broader consumer base.
Read more on LI →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
